Skip to main content

Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study

Neurological Sciences volume 41, pages 2905–2913 (2020)Cite this article

Abstract

Introduction

The approval of 9-δ-tetrahydocannabinol (THC)+cannabidiol (CBD) oromucosal spray (Sativex®) in Italy as an add-on medication for the management of moderate to severe spasticity in multiple sclerosis (MS) has provided a new opportunity for MS patients with drug-resistant spasticity. We aimed to investigate the improvement of MS spasticity-related symptoms in a large cohort of patients with moderate to severe spasticity in daily clinical practice.

Materials and methods

MS patients with drug-resistant spasticity were recruited from 30 Italian MS centers. All patients were eligible for THC:CBD treatment according to the approved label: ≥ 18 years of age, at least moderate spasticity (MS spasticity numerical rating scale [NRS] score ≥ 4) and not responding to the common antispastic drugs. Patients were evaluated at baseline (T0) and after 4 weeks of treatment (T1) with the spasticity NRS scale and were also asked about meaningful improvements in 6 key spasticity-related symptoms.

Results

Out of 1615 enrolled patients, 1432 reached the end of the first month trial period (T1). Of these, 1010 patients (70.5%) reached a ≥ 20% NRS score reduction compared with baseline (initial responders; IR). We found that 627 (43.8% of 1432) patients showed an improvement in at least one spasticity-related symptom (SRSr group), 543 (86.6%) of them belonging to the IR group and 84 (13.4%) to the spasticity NRS non-responders group.

Conclusion

Our study confirmed that the therapeutic benefit of cannabinoids may extend beyond spasticity, improving spasticity-related symptoms even in non-NRS responder patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT et al (2013) Natural history of multiple sclerosis symptoms. Int J MS Care 15(3):146–158. https://doi.org/10.7224/1537-2073.2012-053

    Article  PubMed  PubMed Central  Google Scholar 

  2. Oreja-Guevara C (2012) Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Rev Neurother 12(4 Suppl):3–8. https://doi.org/10.1586/ern.12.11

    Article  CAS  PubMed  Google Scholar 

  3. Vermersch P (2014) MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study. Neurodegener Dis Manag 4(6):407–415. https://doi.org/10.2217/nmt.14.44

    Article  PubMed  Google Scholar 

  4. Flachenecker P, Henze T, Zettl UK (2014) Spasticity in patients with multiple sclerosis–clinical characteristics, treatment and quality of life. Acta Neurol Scand 129(3):154–162. https://doi.org/10.1111/ane.12202

    Article  CAS  PubMed  Google Scholar 

  5. Arroyo R, Massana M, Vila C (2013) Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. Int J Neurosci 123(12):850–858. https://doi.org/10.3109/00207454.2013.812084

    Article  PubMed  Google Scholar 

  6. Svensson J, Borg S, Nilsson P (2014) Costs and quality of life in multiple sclerosis patients with spasticity. Acta Neurol Scand 129(1):13–20. https://doi.org/10.1111/ane.12139

    Article  CAS  PubMed  Google Scholar 

  7. Oreja-Guevara C, Gonzalez-Segura D, Vila C (2013) Spasticity in multiple sclerosis: results of a patient survey. Int J Neurosci 123(6):400–408. https://doi.org/10.3109/00207454.2012.762364

    Article  CAS  PubMed  Google Scholar 

  8. Bensmail D, Vermersch P (2012) Epidemiology and clinical assessment of spasticity in multiple sclerosis. Rev Neurol (Paris) 168(Suppl 3):S45–S50. https://doi.org/10.1016/S0035-3787(12)70046-2

    Article  Google Scholar 

  9. Perez J, Ribera MV (2008) Managing neuropathic pain with Sativex: a review of its pros and cons. Expert Opin Pharmacother 9(7):1189–1195. https://doi.org/10.1517/14656566.9.7.1189

    Article  CAS  PubMed  Google Scholar 

  10. Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S et al (2016) Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry 87(9):944–951. https://doi.org/10.1136/jnnp-2015-312591

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wade DT, Makela P, Robson P, House H, Bateman C (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10(4):434–441. https://doi.org/10.1191/1352458504ms1082oa

    Article  CAS  PubMed  Google Scholar 

  12. Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, Notcutt W, O’Leary C, Ratcliffe S, Nováková I, Zapletalova O, Piková J, Ambler Z (2010) A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 32(5):451–459. https://doi.org/10.1179/016164109X12590518685660

    Article  CAS  PubMed  Google Scholar 

  13. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, Gasperini C, Pozzilli C, Cefaro L, Comi G, Rossi P, Ambler Z, Stelmasiak Z, Erdmann A, Montalban X, Klimek A, Davies P, the Sativex Spasticity Study Group (2011) A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R)) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 18(9):1122–1131. https://doi.org/10.1111/j.1468-1331.2010.03328.x

    Article  CAS  PubMed  Google Scholar 

  14. Colizzi M, McGuire P, Pertwee RG, Bhattacharyya S (2016) Effect of cannabis on glutamate signalling in the brain: a systematic review of human and animal evidence. Neurosci Biobehav Rev 64:359–381. https://doi.org/10.1016/j.neubiorev.2016.03.010

    Article  CAS  PubMed  Google Scholar 

  15. Perez J (2006) Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc) 42(8):495–503. https://doi.org/10.1358/dot.2006.42.8.1021517

    Article  CAS  Google Scholar 

  16. Centonze D (2014) Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways. Eur Neurol 72(Suppl 1):6–8. https://doi.org/10.1159/000367615

    Article  CAS  PubMed  Google Scholar 

  17. Perras C (2005) Sativex for the management of multiple sclerosis symptoms. Issues Emerg Health Technol 72:1–4

    Google Scholar 

  18. Gajofatto A (2016) Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis. Mult Scler Relat Disord 8:64–65. https://doi.org/10.1016/j.msard.2016.05.004

    Article  PubMed  Google Scholar 

  19. Sastre-Garriga J, Vila C, Clissold S, Montalban X (2011) THC and CBD oromucosal spray (Sativex(R)) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurother 11(5):627–637. https://doi.org/10.1586/ern.11.47

    Article  CAS  PubMed  Google Scholar 

  20. Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP (2008) Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 30(5):974–985. https://doi.org/10.1016/j.clinthera.2008.05.011

    Article  PubMed  Google Scholar 

  21. Messina S, Solaro C, Righini I, Bergamaschi R, Bonavita S, Bossio RB et al (2017) Sativex in resistant multiple sclerosis spasticity: discontinuation study in a large population of Italian patients (SA.FE. study). PLoS One 12(8):e0180651. https://doi.org/10.1371/journal.pone.0180651

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Meuth SG, Vila C, Dechant KL (2015) Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis. Expert Rev Neurother 15(8):909–918. https://doi.org/10.1586/14737175.2015.1067607

    Article  CAS  PubMed  Google Scholar 

  23. Serpell MG, Notcutt W, Collin C (2013) Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 260(1):285–295. https://doi.org/10.1007/s00415-012-6634-z

    Article  PubMed  Google Scholar 

  24. Pirone A, Cantile C, Miragliotta V, Lenzi C, Giannessi E, Cozzi B (2016) Immunohistochemical distribution of the cannabinoid receptor 1 and fatty acid amide hydrolase in the dog claustrum. J Chem Neuroanat 74:21–27. https://doi.org/10.1016/j.jchemneu.2016.02.002

    Article  CAS  PubMed  Google Scholar 

  25. McDonough P, McKenna JP, McCreary C, Downer EJ (2014) Neuropathic orofacial pain: cannabinoids as a therapeutic avenue. Int J Biochem Cell Biol 55:72–78. https://doi.org/10.1016/j.biocel.2014.08.007

    Article  CAS  PubMed  Google Scholar 

  26. Mitchell VA, Jeong HJ, Drew GM, Vaughan CW (2011) Cholecystokinin exerts an effect via the endocannabinoid system to inhibit GABAergic transmission in midbrain periaqueductal gray. Neuropsychopharmacology 36(9):1801–1810. https://doi.org/10.1038/npp.2011.59

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Flachenecker P, Henze T, Zettl UK (2014) Nabiximols (THC/CBD oromucosal spray, Sativex(R)) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 71(5–6):271–279. https://doi.org/10.1159/000357427

    Article  CAS  PubMed  Google Scholar 

  28. Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ (2010) Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 16(11):1349–1359. https://doi.org/10.1177/1352458510378020

    Article  CAS  PubMed  Google Scholar 

  29. Maniscalco GT, Aponte R, Bruzzese D, Guarcello G, Manzo V, Napolitano M, Moreggia O, Chiariello F, Florio C (2018) THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study. Neurol Sci 39(1):97–102. https://doi.org/10.1007/s10072-017-3148-6

    Article  PubMed  Google Scholar 

  30. Bartocci C, Evandri MG, Tucci P, Bolle P (2001) Interactions between A-9THC and capsaicin on isolated lamb bladder detrusor. Farmaco. 56(5–7):349–351

    Article  CAS  Google Scholar 

  31. Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M (2004) Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 143(2):247–250. https://doi.org/10.1038/sj.bjp.0705920

    Article  CAS  PubMed  Google Scholar 

  32. Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S (2013) A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 260(4):984–997. https://doi.org/10.1007/s00415-012-6739-4

    Article  CAS  PubMed  Google Scholar 

  33. Arroyo R, Vila C, Dechant KL (2014) Impact of Sativex((R)) on quality of life and activities of daily living in patients with multiple sclerosis spasticity. J Comp Eff Res 3(4):435–444. https://doi.org/10.2217/cer.14.30

    Article  PubMed  Google Scholar 

  34. Coghe G, Pau M, Corona F, Frau J, Lorefice L, Fenu G, Spinicci G, Mamusa E, Musu L, Massole S, Massa R, Marrosu MG, Cocco E (2015) Walking improvements with nabiximols in patients with multiple sclerosis. J Neurol 262(11):2472–2477. https://doi.org/10.1007/s00415-015-7866-5

    Article  CAS  PubMed  Google Scholar 

  35. Marinelli L, Mori L, Canneva S, Colombano F, Curra A, Fattapposta F et al (2016) The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity. Int Clin Psychopharmacol 31(4):232–239. https://doi.org/10.1097/YIC.0000000000000126

    Article  PubMed  Google Scholar 

  36. Leocani L, Nuara A, Houdayer E, Schiavetti I, Del Carro U, Amadio S et al (2015) Sativex((R)) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. J Neurol 262(11):2520–2527. https://doi.org/10.1007/s00415-015-7878-1

    Article  CAS  PubMed  Google Scholar 

  37. Heesen C, Haase R, Melzig S, Poettgen J, Berghoff M, Paul F, Zettl U, Marziniak M, Angstwurm K, Kern R, Ziemssen T, Stellmann JP (2018) Perceptions on the value of bodily functions in multiple sclerosis. Acta Neurol Scand 137(3):356–362. https://doi.org/10.1111/ane.12881

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Patti Francesco and G Chisari Clara contributed equally to this work.

Authors and Affiliations

  1. Department “G.F. Ingrassia”, section of Neurosciences, University of Catania, Catania, Italy

    Francesco Patti, Clara Grazia Chisari & Mario Zappia

  2. Department of Neurology, ASL3 Genovese, and Department of Rehabilitation, ML Novarese Hospital Moncrivello, Genoa, Italy

    Claudio Solaro

  3. Department of Neuroscience, Biomedicine, and Movement Sciences, Section of Neurology, University of Verona, Verona, Italy

    Maria Donata Benedetti

  4. Neurorehabilitation Unit, Department of Neurology, Neurology Institute C. Mondino, Pavia, Italy

    Eliana Berra

  5. Multiple Sclerosis Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

    Assunta Bianco

  6. Neurology Operating Unit and Multiple Sclerosis Center, Provincial Health Authority of Cosenza, Cosenza, Italy

    Roberto Bruno Bossio

  7. Synaptic Immunopathology Lab, Department of Systems Medicine, Tor Vergata University, Rome, Italy

    Fabio Buttari

  8. Neurology Unit, IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy

    Letizia Castelli

  9. Department Neuroscience and Mental Health, Multiple Sclerosis Centre, Health and Science City University Hospital of Turin, Turin, Italy

    Paola Cavalla

  10. Department of Experimental and Clinical Medicine, Neurological Clinic, Marche Polytechnic University, Ancona, Italy

    Raffaella Cerqua

  11. Demyelinating Diseases Centre, Foggia Hospital, Foggia, Italy

    Gianfranco Costantino

  12. Multiple Sclerosis Centre, San Camillo-Forlanini Hospital, Rome, Italy

    Claudio Gasperini

  13. Multiple Sclerosis Center, Medicine Department, Fidenza Hospital, Fidenza, PR, Italy

    Angelica Guareschi

  14. Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy

    Domenico Ippolito

  15. Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II, Naples, Italy

    Roberta Lanzillo & Francesco Saccà

  16. Department of Neurology, Ospedale Cardarelli, Naples, Italy

    Giorgia Teresa Maniscalco

  17. Neurobiology Unit, Neurologia 2, CReSM (Regional Referring Center Multiple Sclerosis), San Luigi Gonzaga University Hospital & Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano, TO, Italy

    Manuela Matta

  18. Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, Bari, Italy

    Damiano Paolicelli

  19. Multiple Sclerosis Centre, University Hospital Pisa, Pisa, Italy

    Loredana Petrucci

  20. Multiple Sclerosis Center of Department of Neurology and Psychiatry of Sapienza, University of Rome, Rome, Italy

    Simona Pontecorvo

  21. Department of NEUROFARBA, University of Florence, Florence, Italy

    Isabella Righini

  22. Multiple Sclerosis Centre, IRCCS-Bonino Pulejo Centre, Messina, Italy

    Margherita Russo

  23. Neuroimmunology Unit, Villa Sofia-Cervello Hospital, Palermo, Italy

    Giovanna Salamone

  24. Department of Clinical and Experimental Medicine, Multiple Sclerosis Center, II Division of Neurology, University of Campania “Luigi Vanvitelli”, Naples, Italy

    Elisabetta Signoriello

  25. Department of Medical Sciences and Public Health, Multiple Sclerosis Center, University of Cagliari, Cagliari, Italy

    Gabriella Spinicci

  26. Azienda Ospedaliera di Rilievo Nazionale, San Giuseppe Moscati, Avellino, Italy

    Daniele Spitaleri

  27. Multiple Sclerosis Center, Unit of Motor Neurorehabilitation, IRCCS Santa Maria Nascente, Fondazione Don Gnocchi, Milan, Italy

    Eleonora Tavazzi

  28. Institute of Neurology, University “Magna Graecia”, Germaneto, Catanzaro, Italy

    Maria Trotta

  29. Multiple Sclerosis Center, ASST della Valle Olona, Gallarate Hospital, Gallarate, VA, Italy

    Mauro Zaffaroni

Authors
  1. Francesco Patti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Clara Grazia Chisari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claudio Solaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Donata Benedetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eliana Berra
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Assunta Bianco
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Roberto Bruno Bossio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fabio Buttari
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Letizia Castelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Paola Cavalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Raffaella Cerqua
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Gianfranco Costantino
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Claudio Gasperini
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Angelica Guareschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Domenico Ippolito
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Roberta Lanzillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Giorgia Teresa Maniscalco
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Manuela Matta
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Damiano Paolicelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Loredana Petrucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Simona Pontecorvo
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Isabella Righini
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Margherita Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Francesco Saccà
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Giovanna Salamone
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Elisabetta Signoriello
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Gabriella Spinicci
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Daniele Spitaleri
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Eleonora Tavazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Maria Trotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. Mauro Zaffaroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. Mario Zappia
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the SA.FE. group

Corresponding author

Correspondence to Francesco Patti.

Ethics declarations

Conflict of interest

Prof Patti has received honoraria for speaking activities by Bayer Schering, Biogen Idec, Merck Serono, Novartis, and Sanofi Aventis; he also served as advisory board member the following companies: Bayer Schering, Biogen Idec, Merck Serono, and Novartis; he was also funded by Pfeizer and FISM for epidemiological studies; finally, he received grant for congress participation from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi Aventis, and TEVA. Dr. Chisari CG received grant for congress participation from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Roche, Sanofi Aventis, and TEVA. Dr. Solaro received honoraria from Biogen, Genzyme, Novartis, Merck Serono, Almirall, Roche, and TEVA. Dr. Bruno Bossio R received grant for advisory board activities from Almirall. Dr. Maniscalco GT received speaking and advisory honoraria from Biogen, Novartis, and TEVA. Dr. Matta M received honoraria for serving in the scientific advisory boards of Almirall, Novartis, Biogen, and Genzyme. Prof. Zappia M has received compensation for consulting services from Boehringer-Ingelheim, Lundbeck, Union Chimique Belge, and scientific grants from AIFA - Agenzia Italiana del Farmaco, Novartis, Lundbeck.

Dr. Benedetti MD, Dr. Berra E, Dr. Bianco A, Dr. Buttari, Dr. Castelli L, Dr. Cavalla P, Dr. Cerqua R, Dr. Costantino GF, Dr. Gasperini C, Dr. Guareschi, Dr. Ippolito D, Dr. Lanzillo R, Dr. Paolicelli D, Dr. Petrucci L, Dr. Pontecorvo S, Dr. Righini I, Dr. Russo M, Dr. Saccà F, Dr. Salamone G, Dr. Signoriello E, Dr. Spinicci G, Dr. Spitaleri D, Dr. Tavazzi E, Dr. Trotta M, and Dr. Zaffaroni M declared that they have no conflict of interest.

Ethics approval

The study was approved by the Policlinico-Vittorio Emanuele (Catania, Italy) Ethics Committee (no. 37/2015/PO) and by the Ethics Committee of the other participating centers.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(XLSX 207 kb).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Patti, F., Chisari, C., Solaro, C. et al. Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study. Neurol Sci 41, 2905–2913 (2020). https://doi.org/10.1007/s10072-020-04413-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-020-04413-6

Keywords

  • Multiple sclerosis
  • Clinical practice
  • Spasticity-related symptoms
  • THC
  • CBD